For millions who live with the debilitating pain of migraine, new research offers encouraging evidence that a relatively new class of drugs – anti-CGRP monoclonal antibodies, or mAbs – can provide sustained relief over a two-year period. While not a cure, these medications are showing promise in significantly reducing the frequency of monthly headache days for a substantial portion of patients. Understanding the long-term effectiveness of anti-CGRP mAbs is crucial as healthcare providers and patients weigh treatment options for this chronic neurological condition.
Migraine affects an estimated 39 million people in the United States, according to the American Migraine Foundation. The condition is characterized by intense, throbbing headaches often accompanied by nausea, vomiting, and sensitivity to light, and sound. Preventive treatments aim to reduce the frequency and severity of these attacks, and anti-CGRP mAbs represent a significant advancement in this area. These medications work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in pain transmission during migraine attacks.
Long-Term Effectiveness and Patient Persistence
A prospective observational study published in Neurology, led by Edoardo Caronna, MD, of Vall d’Hebron Hospital in Barcelona, Spain, investigated the long-term impact of anti-CGRP mAbs. The research team followed 1,340 migraine patients who continued treatment for 24 months, analyzing changes in monthly headache days over time. Their findings, published in March 2026, revealed that at the 24-month mark, 60.4% of patients experienced at least a 50% reduction in monthly headache days. 53.8% demonstrated a sustained response, meaning they maintained that reduction at three or more of four time points throughout the study. This suggests that for many, the benefits of anti-CGRP mAbs aren’t just immediate, but can endure over an extended period.
The study also highlighted the importance of identifying patients who are most likely to benefit from this treatment. Researchers compared the “ON-group” – those who continued treatment for the full 24 months – with a “OFF-group” of 1,057 patients who discontinued treatment due to lack of effectiveness. Significant differences emerged in baseline characteristics between the two groups.
Factors Influencing Treatment Success
Patients in the OFF-group reported a higher number of monthly headache days at the start of the study (25.0 days, compared to 20.0 days in the ON-group). They were also more likely to experience migraine with aura – visual disturbances that often precede a headache – (22.9% vs. 16.2%). Notably, the presence of co-existing conditions like depression (37.9% vs. 22.8%) and obesity (19.1% vs. 7.2%) were also significantly more common in the group who ultimately stopped treatment. These findings suggest that individuals with more frequent headaches, aura, and co-morbidities may face greater challenges in achieving long-term success with anti-CGRP mAbs.
Researchers emphasize that these factors don’t necessarily preclude treatment, but rather underscore the need for a personalized approach. “Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence,” the study authors wrote. This suggests that careful patient selection and management of co-existing conditions could optimize treatment outcomes.
The Role of Body Weight and Pharmacokinetics
The study also points to a potential link between body weight and treatment effectiveness. The researchers noted the need for further investigation into how body weight might impact the pharmacokinetics – the way the body processes the drug – of anti-CGRP mAbs. Here’s an area of growing interest, as variations in drug metabolism can influence how well a medication works. Understanding these interactions could lead to more tailored dosing strategies and improved outcomes for patients across a range of body types.
What Which means for Migraine Sufferers
The findings from Dr. Caronna and his team provide valuable insights for both patients and healthcare providers. While anti-CGRP mAbs aren’t a guaranteed solution for everyone, the study demonstrates that a significant proportion of patients can experience sustained reductions in migraine frequency with this treatment. Open communication with a neurologist is essential to determine if anti-CGRP mAbs are a suitable option, and to address any co-existing conditions that might impact treatment success. The research reinforces the importance of a comprehensive approach to migraine management, encompassing lifestyle modifications, other medications, and ongoing monitoring.
The study provides Class IV evidence, meaning it’s based on observational data and doesn’t establish a definitive cause-and-effect relationship. Still, it adds to a growing body of evidence supporting the long-term benefits of anti-CGRP mAbs for many migraine sufferers. Further research is needed to refine patient selection criteria and optimize treatment strategies, but this study offers a hopeful outlook for those seeking lasting relief from this debilitating condition.
Looking ahead, researchers will continue to explore the factors that influence treatment response and persistence with anti-CGRP mAbs. Ongoing studies are investigating the potential for personalized dosing regimens and the impact of different formulations of these medications. The next major update from the research team is expected in late 2026, when they plan to present findings on the relationship between body mass index and drug efficacy.
Have you or someone you realize experienced relief from migraines using anti-CGRP mAbs? Share your thoughts and experiences in the comments below.
Related reading
